Skip to main content

MY-E Side Effects

Generic name: erythromycin

Medically reviewed by Last updated on Mar 15, 2024.

Note: This document contains side effect information about erythromycin. Some dosage forms listed on this page may not apply to the brand name MY-E.

Applies to erythromycin: oral capsule delayed release, oral powder for suspension, oral tablet, oral tablet delayed release, oral tablet enteric coated. Other dosage forms:


Oral route (Suspension)

Erythromycin estolate is contraindicated in patients with preexisting liver disease. Hepatic dysfunction with or without jaundice has occurred, mainly in adults. It may be accompanied by malaise, nausea, vomiting, abdominal colic, fever, and in some instances, severe abdominal pain may lead to an abdominal surgical emergency. Discontinue erythromycin promptly if the above findings occur.

Serious side effects of MY-E

Along with its needed effects, erythromycin (the active ingredient contained in MY-E) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking erythromycin:


Incidence not known

Other side effects of MY-E

Some side effects of erythromycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to erythromycin: compounding powder, injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral granule for reconstitution, oral suspension, oral tablet, oral tablet chewable, oral tablet coated particles.


The most commonly reported side effect included localized irritation, abdominal cramping, abdominal discomfort, and decreased appetite.[Ref]


Common (1% to 10%): Abdominal cramping, abdominal pain, diarrhea, flatulence, infantile hypertrophic pyloric stenosis, nausea, severe nonĀ¬-bilious vomiting, soft defecation, vomiting

Uncommon (0.1% to 1%): Abdominal discomfort, oral candidiasis

Rare (0.01% to 0.1%): Pancreatitis, pseudomembranous colitis

Very rare (less than 0.01%): Spastic hypertrophic pyloric stenosis (in children)[Ref]

Abdominal pain, diarrhea, nausea, and vomiting may occur with treatment, and appear to be dose-related.

In a study with 157 infants given oral formations for pertussis prophylaxis, 7 (approximately 5%) developed irritability with feeding and severe, non-bilious vomiting associated with IHPS.

Pseudomembranous colitis may occur during or after treatment.[Ref]


Anorexia may occur with treatment, and appears to be dose-related.[Ref]

Common (1% to 10%): Anorexia, decreased appetite[Ref]


Common (1% to 10%): Thrombophlebitis

Uncommon (0.1% to 1%): Chest pain, palpitations

Rare (0.01% to 0.1%): Atypical ventricular tachycardia, palpitations, QT interval prolongation/QT prolongation, torsade de pointes, ventricular arrhythmias/fatal ventricular arrhythmias

Very rare (less than 0.01%): Cardiac arrhythmias

Frequency not reported: Cardiac rhythmic disorders, hypotension, ventricular tachyarrhythmias, ventricular tachycardia[Ref]


Common (1% to 10%): Local irritation

Uncommon (0.1% to 1%): Venous irritation

Rare (0.01% to 0.1%): Pain, vessel trauma[Ref]

Slow infusion of diluted parenteral formulations (continuously or intermittently via IV over no less than 20 to 60 minutes) may alleviate venous trauma and pain.[Ref]


Common (1% to 10%): Muscle spasms

Rare (0.01% to 0.1%): Joint swelling, rhabdomyolysis

Very rare (less than 0.01%): Myasthenia gravis unmasking, myasthenia gravis worsening[Ref]


Common (1% to 10%): Irritability with feeding

Rare (0.01% to 0.1%): Neonatal irritability

Frequency not reported: Confusion, confusional state, hallucinations[Ref]


Uncommon (0.1% to 1%): Erythema, exanthema, mild rash, pruritus, urticaria, urticarial exanthema

Rare (0.01% to 0.1%): Erythema multiforme, mild skin eruptions, skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis

Frequency not reported: Acute generalized exanthematous pustulosis (AGEP), bullous fixed eruptions, eczema, rashes with/without pruritus, skin eruptions, upper abdominal discomfort[Ref]


Abnormal liver function test results, hepatitis, and/or liver dysfunction may occur with oral formulations.[Ref]

Uncommon (0.1% to 1%): Alkaline phosphatase elevations, ALT elevations, AST elevations, elevation of liver enzymes, GGT elevations

Rare (0.01% to 0.1%): Cholestasis, cholestatic jaundice

Very rare (less than 0.01%): Abnormal liver function test results, hepatitis, hepatomegaly, liver dysfunction with/without jaundice, liver failure

Frequency not reported: Cholestatic hepatitis, hepatocellular hepatitis, jaundice, liver dysfunction[Ref]


Uncommon (0.1% to 1%): Overgrowth of nonsusceptible bacteria, overgrowth of nonsusceptible fungi[Ref]


Uncommon (0.1% to 1%): Hypersensitivity

Rare (0.01% to 0.1%): Allergic edema, allergic reactions, anaphylactic reaction, anaphylactic shock, anaphylaxis, angioedema

Frequency not reported: Serious allergic reactions[Ref]


Uncommon (0.1% to 1%): Reversible hearing loss

Rare (0.01% to 0.1%): Pyrexia

Very rare (less than 0.01%): Deafness, reversible deafness, tinnitus

Frequency not reported: Discomfort, fever, malaise[Ref]

Reversible hearing loss was more frequently reported in patients with renal or liver dysfunction.

Older patients, especially those with liver and/or renal dysfunction, may be at higher risk of developing increased risk of hearing loss, especially when given doses of at least 4 grams/day.[Ref]


Uncommon (0.1% to 1%): Vaginal candidiasis[Ref]


Uncommon (0.1% to 1%): Lactate dehydrogenase (LDH) elevations[Ref]

Nervous system

Rare (0.01% to 0.1%): Central nervous system (CNS) damage, convulsions, seizures

Frequency not reported: Dizziness, headache, mitochondrial optic neuropathy, somnolence, transient CNS side effects, vertigo[Ref]


Rare (0.01% to 0.1%): Damage to the kidneys

Very rare (less than 0.01%): Tubulointerstitial nephritis

Frequency not reported: Interstitial nephritis[Ref]


Rare (0.01% to 0.1%): Damage to the blood

Frequency not reported: Eosinophilia[Ref]


Frequency not reported: Blurred vision, diplopia, visual impairment[Ref]


Frequency not reported: Asthmatic states, dyspnea[Ref]

Frequently asked questions


1. "Product Information. Eryc (erythromycin)." Parke-Davis

2. (2022) "Product Information. Ery-Tab (erythromycin)." Abbott Pharmaceutical

3. (2003) "Product Information. Erythrocin Lactobionate (erythromycin)." Abbott Pharmaceutical

4. Cerner Multum, Inc. "UK Summary of Product Characteristics."

5. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.